At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 228 enrolled
Drug / intervention
pazopanib (GW786034) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen
In Brief
A Phase 2 clinical trial evaluating pazopanib (GW786034) and lapatinib (GW572016) for Neoplasms, Uterine Cervix and Metastatic Cervical Cancer. Completed, enrolled 228 participants across 63 sites in 13 countries.
Detailed Summary
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Belgium, Canada, Estonia, France, Germany, India, Ireland, Italy, Mexico, Spain, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedFeb 2007
Primary CompletionJul 2008
Study CompletionJul 2011
TodayJul 2026
First PostedFeb 2, 2007
Enrollment StartNov 1, 2006
Primary CompletionJul 1, 2008
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.4 years ago
Interventions
pazopanib (GW786034)drug
lapatinib (GW572016)drug